Sulfation of heparan sulfate associated with amyloid-β plaques in patients with Alzheimer’s disease

被引:0
作者
Ilona B. Bruinsma
Luuk te Riet
Tom Gevers
Gerdy B. ten Dam
Toin H. van Kuppevelt
Guido David
Benno Küsters
Robert M. W. de Waal
Marcel M. Verbeek
机构
[1] Donders Institute for Brain,Department of Neurology and Alzheimer Centre
[2] Cognition and Behaviour,Laboratory of Pediatrics and Neurology
[3] Centre for Neuroscience,Department of Biochemistry
[4] Radboud University Nijmegen Medical Centre,Department of Human Genetics
[5] Donders Institute for Brain,Department of Pathology
[6] Cognition and Behaviour,undefined
[7] Centre for Neuroscience,undefined
[8] Radboud University Nijmegen Medical Centre,undefined
[9] Nijmegen Centre for Molecular Life Sciences,undefined
[10] Radboud University Nijmegen Medical Centre,undefined
[11] University of Leuven and Flanders Interuniversity Institute for Biotechnology,undefined
[12] Donders Institute for Brain,undefined
[13] Cognition and Behaviour,undefined
[14] Centre for Neuroscience,undefined
[15] Radboud University Nijmegen Medical Centre,undefined
来源
Acta Neuropathologica | 2010年 / 119卷
关键词
Alzheimer’s disease; Amyloid-β plaques; Heparan sulfate; Sulfation;
D O I
暂无
中图分类号
学科分类号
摘要
Alzheimer’s disease (AD) is characterized by pathological lesions such as amyloid-β (Aβ) plaques and cerebral amyloid angiopathy. Both these lesions consist mainly of aggregated Aβ protein and this aggregation is affected by macromolecules such as heparan sulfate (HS) proteoglycans. Previous studies demonstrated that HS enhances fibrillogenesis of Aβ and that this enhancement is dependent on the degree of sulfation of HS. In addition, it has been reported that these sulfation epitopes do not occur randomly but have a defined tissue distribution. Until now, the distribution of sulfation epitopes of HS has not yet been studied in human brain. We investigated whether a specific HS epitope is associated with Aβ plaques by performing immunohistochemistry on occipital neocortical and hippocampal tissue sections from AD patients using five HS epitope-specific phage display antibodies. Antibodies recognizing highly N-sulfated HS demonstrated the highest level of staining in both fibrillar Aβ plaques and non-fibrillar Aβ plaques, whereas antibodies recognizing HS regions with a lower degree of N-sulfate modifications were only immunoreactive with fibrillar Aβ plaques. Thus, our results suggest that a larger variety of HS epitopes is associated with fibrillar Aβ plaques, but the HS epitopes associated with non-fibrillar Aβ plaques seem to be more restricted, selectively consisting of highly N-sulfated epitopes.
引用
收藏
页码:211 / 220
页数:9
相关论文
共 158 条
[1]  
Braak H(1991)Neuropathological staging of Alzheimer-related changes Acta Neuropathol (Berl) 82 239-259
[2]  
Braak E(1998)Sulfate content and specific glycosaminoglycan backbone of perlecan are critical for perlecan’s enhancement of islet amyloid polypeptide (amylin) fibril formation Diabetes 47 612-620
[3]  
Castillo GM(1999)The sulfate moieties of glycosaminoglycans are critical for the enhancement of beta-amyloid protein fibril formation J Neurochem 72 1681-1687
[4]  
Cummings JA(1997)Perlecan binds to the beta-amyloid proteins (A beta) of Alzheimer’s disease, accelerates A beta fibril formation, and maintains A beta fibril stability J Neurochem 69 2452-2465
[5]  
Yang W(2001)Structure and biological interactions of heparin and heparan sulfate Adv Carbohydr Chem Biochem 57 159-206
[6]  
Castillo GM(2000)Agrin binds to beta-amyloid (Abeta), accelerates abeta fibril formation, and is localized to Abeta deposits in Alzheimer’s disease brain Mol Cell Neurosci 15 183-198
[7]  
Lukito W(1992)Developmental changes in heparan sulfate expression: in situ detection with mAbs J Cell Biol 119 961-975
[8]  
Wight TN(2002)Large, tissue-regulated domain diversity of heparan sulfates demonstrated by phage display antibodies J Biol Chem 277 10982-10986
[9]  
Snow AD(2001)Molecular diversity of heparan sulfate J Clin Invest 108 169-173
[10]  
Castillo GM(1993)Heparan sulfate expression patterns in the amyloid deposits of patients with Alzheimer’s and Lewy body type dementia Dementia 4 308-314